Biomasys accepted into the prestigious Accelerate programme at the University of Cambridge.

Biomasys is a diagnostic healthtech startup committed to providing rapid and affordable diagnostics to the most needy in the global south and underserved Western health markets. We’re developing a novel device which leverages machine learning in the identification and detection of biomarkers predictive of miscarriages and preterm births.

It is estimated that 10 per cent of pregnancies in the developing world result in miscarriage or preterm birth. About 810 women die daily from preventable causes related to pregnancy and childbirth, 94 per cent of which are in low and lower middle-income countries. We believe our solution can become a global standard for antenatal care and save millions of lives in the process.

Continue Reading

Leave a Comment

Your email address will not be published.

Scroll to Top